All Journals > Clinical Infectious Diseases > 15 January 2008 > The Epidemic of Antibiotic‐Resistant Infections

Article Tools

Search for Related Articles

  • By Author
  • Search In

Announcements

CID LISTED AMONG
“MOST INFLUENTIAL”

Clinical Infectious Diseases has been named as one of the "100 Most Influential Journals in Biology and Medicine" of the past 100 years by the Special Libraries Association. The list was compiled by the 680-plus members of SLA’s Biomedical and Life Sciences Division.

See the full list here.

Source: The DBIO 100, the 100 Most Influential Journals in Biology & Medicine over the last 100 Years

In the News

Featured in MSNBC
"Germs and flu are up; infection control is down" June 9, 2009
Trends in the Incidence of Methicillin‐Resistant Staphylococcus aureus Infection in Children’s Hospitals in the United States
Jeffrey S. Gerber, Susan E. Coffin, Sarah A. Smathers, and Theoklis E. Zaoutis
Just this week, researchers reported that the incidence of MRSA infections among children admitted to pediatric hospitals in the United States more than tripled between 2002 and 2007. Researchers at the Children’s Hospital of Philadelphia and the University of Pennsylvania found cases of MRSA jumped from 6.7 per 1,000 admissions in 2002 to 21.1 cases per 1,000 admissions in 2007, according to a study released online Monday in the journal Clinical Infectious Diseases.

Featured in Toronto Star
"Pigs, viruses and politics" May 2, 2009
Are Swine Workers in the United States at Increased Risk of Infection with Zoonotic Influenza Virus?
Kendall P. Myers, Christopher W. Olsen, Sharon F. Setterquist, Ana W. Capuano, Kelley J. Donham, Eileen L. Thacker, James A. Merchant, and Gregory C. Gray
Another study, this one published in the U.S. journal Clinical Infectious Diseases in 2006, found that workers in meat-processing plants have a greater likelihood of being infected by some version of the H1N1 flu virus than the general population (the odds of pig farmers getting the disease are significantly greater again).

Featured in Philadelphia Inquirer
"A shot in the arm for vaccines" April 19, 2009
Vaccines: Pneumococcal Vaccination of Elderly Adults: New Paradigms for Protection
Lisa A. Jackson and Edward N. Janoff
Every year, an estimated 915,000 people 65 and older get pneumonia, and 40 percent of them end up in hospitals, according to a 2004 paper in the journal Clinical Infectious Diseases. Pneumonia often kills older people, said Richard Stefanacci, a geriatrician at the University of the Sciences in Philadelphia.

15 January 2008

Volume 46, Number 2
Clinical Infectious Diseases 2008;46:155–164
© 2007 by the Infectious Diseases Society of America. All rights reserved.
1058-4838/2008/4602-0001$15.00
DOI: 10.1086/524891
IDSA PUBLIC POLICY

The Epidemic of Antibiotic‐Resistant Infections: A Call to Action for the Medical Community from the Infectious Diseases Society of America

Brad Spellberg,1,2

Robert Guidos,5

David Gilbert,7

John Bradley,3,4

Helen W. Boucher,8

W. Michael Scheld,6

John G. Bartlett,9 and

John Edwards, Jr., 1,2 for

the Infectious Diseases Society of America

1Division of Infectious Diseases, Harbor–University of California–Los Angeles (UCLA) Medical Center, Torrance, 2Geffen School of Medicine, UCLA, Los Angeles, and 3Children’s Hospital San Diego and 4University of California at San Diego, California; 5Infectious Diseases Society of America, Alexandria, and 6Division of Infectious Diseases, University of Virginia Health System, Charlottesville, Virginia; 7Division of Infectious Diseases, Providence Portland Medical Center and Oregon Health Sciences University, Portland, Oregon; 8Tufts–New England Medical Center, Boston, Massachusetts; and 9Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland

The ongoing explosion of antibiotic‐resistant infections continues to plague global and US health care. Meanwhile, an equally alarming decline has occurred in the research and development of new antibiotics to deal with the threat. In response to this microbial “perfect storm,” in 2001, the federal Interagency Task Force on Antimicrobial Resistance released the “Action Plan to Combat Antimicrobial Resistance; Part 1: Domestic” to strengthen the response in the United States. The Infectious Diseases Society of America (IDSA) followed in 2004 with its own report, “Bad Bugs, No Drugs: As Antibiotic Discovery Stagnates, A Public Health Crisis Brews,” which proposed incentives to reinvigorate pharmaceutical investment in antibiotic research and development. The IDSA’s subsequent lobbying efforts led to the introduction of promising legislation in the 109th US Congress (January 2005–December 2006). Unfortunately, the legislation was not enacted. During the 110th Congress, the IDSA has continued to work with congressional leaders on promising legislation to address antibiotic‐resistant infection. Nevertheless, despite intensive public relations and lobbying efforts, it remains unclear whether sufficiently robust legislation will be enacted. In the meantime, microbes continue to become more resistant, the antibiotic pipeline continues to diminish, and the majority of the public remains unaware of this critical situation. The result of insufficient federal funding; insufficient surveillance, prevention, and control; insufficient research and development activities; misguided regulation of antibiotics in agriculture and, in particular, for food animals; and insufficient overall coordination of US (and international) efforts could mean a literal return to the preantibiotic era for many types of infections. If we are to address the antimicrobial resistance crisis, a concerted, grassroots effort led by the medical community will be required.

Received 21 September 2007; accepted 24 September 2007; electronically published 5 December 2007.

Reprints or correspondence: Dr. John Edwards, Jr., Div. of Infectious Diseases, Harbor‐UCLA Medical Center, 1124 W. Carson St., RB2, Torrance, CA 90502 ()

Cited by

Brad Spellberg, George H. Talbot, Helen W. Boucher, John S. Bradley, David Gilbert, W. Michael Scheld, John Edwards, Jr., and John G. Bartlett, for the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. (2009) Antimicrobial Agents for Complicated Skin and Skin‐Structure Infections: Justification of Noninferiority Margins in the Absence of Placebo‐Controlled Trials. Clinical Infectious Diseases 49:3, 383-391
Online publication date: 1-Aug-2009.
Abstract-Full Text-PDF Version (349 kB)
D. Mertz, M. Koller, P. Haller, M. L. Lampert, H. Plagge, B. Hug, G. Koch, M. Battegay, U. Fluckiger, S. Bassetti. (2009) Outcomes of early switching from intravenous to oral antibiotics on medical wards. Journal of Antimicrobial Chemotherapy 64:1, 188-199
Online publication date: 1-Aug-2009.
CrossRef
E J Septimus, K M Kuper. (2009) Clinical Challenges in Addressing Resistance to Antimicrobial Drugs in the Twenty-First Century. Clinical Pharmacology & Therapeutics
Online publication date: 1-Aug-2009.
CrossRef
S. E. Blair, N. N. Cokcetin, E. J. Harry, D. A. Carter. (2009) The unusual antibacterial activity of medical-grade Leptospermum honey: antibacterial spectrum, resistance and transcriptome analysis. European Journal of Clinical Microbiology & Infectious Diseases
Online publication date: 10-Jul-2009.
CrossRef
Maria del Mar Fernández de Gatta, Dolores Santos Buelga, Amparo Sánchez Navarro, Alfonso Dominguez-Gil, Maria Jose García. (2009) Vancomycin Dosage Optimization in Patients with Malignant Haematological Disease by Pharmacokinetic/Pharmacodynamic Analysis. Clinical Pharmacokinetics 48:4, 273-280
Online publication date: 1-Jul-2009.
CrossRef
Jason A. Roberts, Steven Webb, David Paterson, Kwok M. Ho, Jeffrey Lipman. (2009) A systematic review on clinical benefits of continuous administration of β-lactam antibiotics*. Critical Care Medicine 37:6, 2071-2078
Online publication date: 1-Jul-2009.
CrossRef
Catherine D. Cooksley, Elenir B. C. Avritscher, Kenneth V. Rolston, Linda S. Elting. (2009) Hospitalizations for infection in cancer patients: impact of an aging population. Supportive Care in Cancer 17:5, 547-554
Online publication date: 1-Jun-2009.
CrossRef
Katy L. Blake, Alex J. O'Neill, Dominique Mengin-Lecreulx, Peter J. F. Henderson, Julieanne M. Bostock, Colin J. Dunsmore, Katie J. Simmons, Colin W. G. Fishwick, Jennifer A. Leeds, Ian Chopra. (2009) The nature of Staphylococcus aureus MurA and MurZ and approaches for detection of peptidoglycan biosynthesis inhibitors. Molecular Microbiology 72:2, 335-343
Online publication date: 1-May-2009.
CrossRef
Ulrike Holzgrabe. (2009) Neue Antibiotika in Sicht?. Pharmazie in unserer Zeit 38:2, 106-108
Online publication date: 1-Apr-2009.
CrossRef
E. O'Fallon, A. Pop-Vicas, E. D'Agata. (2009) The Emerging Threat of Multidrug-Resistant Gram-Negative Organisms in Long-Term Care Facilities. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 64A:1, 138-141
Online publication date: 20-Feb-2009.
CrossRef
Helen W. Boucher, George H. Talbot, John S. Bradley, John E. Edwards, Jr, David Gilbert, Louis B. Rice, Michael Scheld, Brad Spellberg, and John Bartlett. (2009) Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America. Clinical Infectious Diseases 48:1, 1-12
Online publication date: 1-Jan-2009.
Abstract-Full Text-PDF Version (324 kB)
L. R. Peterson. (2009) Currently available antimicrobial agents and their potential for use as monotherapy. Clinical Microbiology and Infection 14, 30-45
Online publication date: 1-Jan-2009.
CrossRef
T. Edgar, S. D. Boyd, M. J. Palame. (2008) Sustainability for behaviour change in the fight against antibiotic resistance: a social marketing framework. Journal of Antimicrobial Chemotherapy 63:2, 230-237
Online publication date: 19-Dec-2008.
CrossRef
Helen W. Boucher. (2008) Is It Possible to Blind a Trial for Community‐Acquired Pneumonia?. Clinical Infectious Diseases 47:s3, S210-S215
Online publication date: 1-Dec-2008.
Abstract-Full Text-PDF Version (221 kB)
Brad Spellberg, Thomas R. Fleming, and David N. Gilbert. (2008) Executive Summary: Workshop on Issues in the Design and Conduct of Clinical Trials of Antibacterial Drugs in the Treatment of Community‐Acquired Pneumonia. Clinical Infectious Diseases 47:s3, S105-S107
Online publication date: 1-Dec-2008.
Citation-Full Text-PDF Version (145 kB)
Infectious Diseases Society of America. (2008) Position Paper: Recommended Design Features of Future Clinical Trials of Antibacterial Agents for Community‐Acquired Pneumonia. Clinical Infectious Diseases 47:s3, S249-S265
Online publication date: 1-Dec-2008.
Citation-Full Text-PDF Version (335 kB)
Glenn S. Tillotson and Roger M. Echols. (2008) Clinical Trial Design and Consequences for Drug Development for Community‐Acquired Pneumonia: An Industry Perspective. Clinical Infectious Diseases 47:s3, S237-S240
Online publication date: 1-Dec-2008.
Abstract-Full Text-PDF Version (215 kB)
Matthew E Falagas, Alexandros P Grammatikos, Argyris Michalopoulos. (2008) Potential of old-generation antibiotics to address current need for new antibiotics. Expert Review of Anti-infective Therapy 6:5, 593-600
Online publication date: 1-Nov-2008.
CrossRef
Lynne V McFarland. (2008) Antibiotic-associated diarrhea: epidemiology, trends and treatment. Future Microbiology 3:5, 563-578
Online publication date: 1-Nov-2008.
CrossRef
Lucia Pallecchi, Alessandro Bartoloni, Franco Paradisi, Gian Maria Rossolini. (2008) Antibiotic resistance in the absence of antimicrobial use: mechanisms and implications. Expert Review of Anti-infective Therapy 6:5, 725-732
Online publication date: 1-Nov-2008.
CrossRef
Marin H. Kollef, Lena M. Napolitano, Joseph S. Solomkin, Richard G. Wunderink, In‐Gyu Bae, Vance G. Fowler, Robert A. Balk, Dennis L. Stevens, James J. Rahal, Andrew F. Shorr, Peter K. Linden, and Scott T. Micek. (2008) Health Care–Associated Infection (HAI): A Critical Appraisal of the Emerging Threat—Proceedings of the HAI Summit. Clinical Infectious Diseases 47:s2, S55-S99
Online publication date: 1-Oct-2008.
Abstract-Full Text-PDF Version (860 kB)
R. Monina Klevens, Jonathan R. Edwards, and R. P. Gaynes, for the National Nosocomial Infections Surveillance System. (2008) The Impact of Antimicrobial‐Resistant, Health Care–Associated Infections on Mortality in the United States. Clinical Infectious Diseases 47:7, 927-930
Online publication date: 1-Oct-2008.
Abstract-Full Text-PDF Version (228 kB)
Oguz Resat Sipahi. (2008) Economics of antibiotic resistance. Expert Review of Anti-infective Therapy 6:4, 523-539
Online publication date: 1-Sep-2008.
CrossRef
Brad Spellberg. (2008) Dr. William H. Stewart: Mistaken or Maligned?. Clinical Infectious Diseases 47:2, 294-294
Online publication date: 15-Jul-2008.
Citation-Full Text-PDF Version (314 kB)
Jared Crandon, David P Nicolau. (2008) Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens. Future Microbiology 3:3, 251-263
Online publication date: 1-Jul-2008.
CrossRef
Calvin M. Kunin. (2008) Why Did It Take the Infectious Diseases Society of America So Long to Address the Problem of Antibiotic Resistance?. Clinical Infectious Diseases 46:11, 1791-1792
Online publication date: 1-Jun-2008.
Citation-Full Text-PDF Version (388 kB)
Brad Spellberg, David Gilbert, John Bradley, Helen W. Boucher, William M. Scheld, John G. Bartlett, and John E. Edwards, Jr.. (2008) Reply to Kunin: Rationale for Antibiotic Development Incentives. Clinical Infectious Diseases 46:11, 1792-1793
Online publication date: 1-Jun-2008.
Citation-Full Text-PDF Version (388 kB)
Back to Top
Close Popup